Compare Vanguard Total World Stock Index Fund ETF (VT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total World Stock Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Total World Stock Index Fund ETF trades at $156.36, while State Street SPDR S&P Biotech ETF trades at $154.34. Which is the better fit depends on your goals.
| VT | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $159.35 | $164.28 |
52-Week Low | $128.41 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vanguard Total World Stock ETF (VT) trades at $154.29, down 0.32% on the day, with technical indicators showing a bearish bias despite neutral oscillators. The ETF provides diversified global equity exposure with over 10,000 stocks across developed and emerging markets. Recent news highlights institutional interest, with Alta Advisers Ltd increasing its position by 18.5% in Q1 2026 (SEC filing, 2026-07-21).
VT offers broad global diversification with a low 0.06% expense ratio, appealing for long-term investors seeking worldwide market exposure. Key risks include global economic volatility and currency fluctuations. The bearish technical signals suggest near-term pressure, but the fund's comprehensive coverage provides stability for portfolio construction.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
